

Pseudo-Enantiomeric Carbohydrate-Based N-Heterocyclic Carbenes as Promising Chiral Ligands for Enantiotopic Discrimination

Alexander S. Henderson, John F. Bower* and M. Carmen Galan*

School of Chemistry, Cantock's Close, University of Bristol, Bristol, BS8 1TS, UK.


Supporting Information

Table of Contents

General Experiment Details	S2
Experimental Procedures and Data	S3
References	S19
NMR Spectra of Novel Compounds	S20


General Experiment Details:

Commercial starting materials were used without further purification unless stated. Carbohydrate substrates were left under high vacuum for (minimum) 1 h prior to initiating reactions. Dry solvents were obtained by distillation or by passage through a column of anhydrous alumina and transferred anhydrously. All reactions were performed under inert atmospheres – unless otherwise stated – of N₂ or Ar by employing Schlenk techniques in conjunction with oven / flame dried glassware. Commercially available Merck Kieselgel 60F₂₅₄ aluminium backed plates were used for TLC analysis. TLC plates were stained with acid, ninhydrin, KMnO₄, vanillin, or a combination thereof, solutions and thermally developed. FCC was performed according to Still,¹ using Fluorochem 60 silica (40-63 μm particle size). Solvents for flash column chromatography (FCC) and thin layer chromatography (TLC) are listed in volume:volume percentages. Infra-red spectra were recorded in the range 4000-650 cm⁻¹ on a Perkin Elmer Spectrum either as neat films or solids compressed onto a diamond window. NMR spectra were recorded on an ECS 400, Varian 400 MHz or Varian 500 MHz spectrometers at 25.0 °C unless otherwise stated. Chemical shifts are quoted in ppm with spectra referenced to the residual protium of the deuterated solvent. Coupling constants are quoted to the nearest 0.5 Hz. Other abbreviations used are: br (broad), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and *app.* (apparent). Assignments of ¹H NMR and ¹³C NMR signals were made where possible, using COSY, DEPT, HMQC, HSQC and HMBC experiments. Mass spectra were determined by the University of Bristol mass spectrometry service by either; chemical ionisation (CI), electrospray ionisation (ESI) or by matrix-assisted laser deposition/ionization (MALDI) modes. Single crystal analysis was performed on a Bruker-AXS Microstar or a Kappa Apex II diffractometer. Enantiomeric excess was determined by high performance liquid chromatography (HPLC) using an Agilent Infinity 1260 instrument in conjunction with Chiralpak IA, IB and IC columns. Petrol refers to petroleum ether 40-60. See below for carbohydrate numbering nomenclature in pyranoside and furanoside systems.



Experimental Procedures and Data:


Synthesis of a building block **8a** with steric bulk at C1



Phenyl 2-amino-3,4,6-tri-*O*-methyl-2,1-dideoxy-1-thio- β -D-glucopyranoside (**8a**):

To a solution of azide **7**² (317 mg, 0.93 mmol) in EtOH (5% wt 12 M HCl, 0.2 M) under Ar at rt, was added Pd (5% wt on C, 10 mol%). H_2 (1 atm, balloon) was bubbled through the solvent until the Ar atmosphere was replaced. After 4 h, the H_2 was displaced by a stream of N_2 and the suspension was neutralised with sat. aq. NaHCO_3 . The reaction mixture was filtered through Celite[®] using EtOH as eluent to afford a colourless solution. Concentration *in vacuo* and subsequent trituration with MeOH (3 x washes) yielded **8a** (280 mg, 96%) as a colourless solid. $R_f = 0.8$ (90:10 CH_2Cl_2 :MeOH); $\nu_{\text{max}} / \text{cm}^{-1}$ (film): 3403, 2902, 1599, 1504, 1388, 1063; ^1H NMR (500 MHz, CDCl_3) δ : 7.53-7.51 (2H, m, ArCH), 7.29-7.25 (3H, m, ArCH), 4.41 (1H, d, $J = 10.0$ Hz, H-1), 3.64 (1H, dd, $J = 11.0$ and 2.0 Hz, H-6a), 3.63 (3H, s, OCH_3), 3.59 (1H, dd, $J = 11.0$ and 4.5 Hz, H-6b), 3.51 (3H, s, OCH_3), 3.40 (3H, s, OCH_3), 3.34 (1H, ddd, $J = 9.0$, 4.5 and 2.0 Hz, H-5), 3.21 (1H, *app. t*, $J = 10.0$, H-4), 3.06 (1H, *app. t*, $J = 9.0$ Hz, H-3), 2.75 (1H, *app. t*, $J = 9.5$ Hz, H-2), 1.70 (2H, br s, NH_2); ^{13}C NMR (125 MHz, CDCl_3) δ : 132.9 (ArC), 132.4 (ArCH), 132.4 (ArCH), 128.8 (ArCH), 127.7 (ArCH), 89.3 (C-1), 88.2 (C-3), 79.8 (C-4), 79.2 (C-5), 71.4 (C-6), 60.9 (OCH_3), 60.2 (OCH_3), 59.4 (OCH_3), 55.6 (C-2); m/z HRMS (ESI): Found $[\text{M}+\text{Na}]^+$ 336.1240, $\text{C}_{15}\text{H}_{23}\text{NO}_4\text{SNa}$ requires 336.1240; $[\alpha]_D^{24} = -4$ (c 1.2, CHCl_3).

Synthesis of a carbohydrate-based imidazolium salt with steric bulk at C1



Bis(phenyl 2-amino-3,4,6-tri-*O*-methyl-2,1-dideoxy-1-thio- β -D-glucopyranoside)-*N,N'*-iminoethylidene (**S4**):

To a solution of amine **8a** (761 mg, 2.18 mmol) and glyoxal (aq. 40%, 1.14 mmol) in anhydrous MeOH (0.5 M) at rt, was added MgSO₄ (0.5 g per mmol). After 18 h, the reaction was diluted with CHCl₃ (10 mL), filtered and then concentrated. Purification by trituration with cool Et₂O (2 x 5 mL) yielded bis(imine) **S4** as a colourless solid. Note: bis(imine)s were generally insoluble in MeOH and soluble in CHCl₃. *R*_f = 0.9 (90:10 CH₂Cl₂:MeOH); ν_{max} / cm⁻¹ (film): 2932, 2834, 1721, 2629, 1583, 1479, 1375, 1139, 1104; ¹H NMR (500 MHz, CDCl₃) δ : 7.75 (2H, s, HC=N), 7.51-5.49 (4H, m, ArCH), 7.29-7.25 (6H, m, ArCH), 4.91 (2H, d, *J* = 10.0 Hz, H-1), 3.70 (2H, dd, *J* = 11.0 and 2.0 Hz, H-6a), 3.64 (2H, dd, *J* = 11.0 and 4.5 Hz, H-6b), 3.54 (6H, s, OCH₃), 3.47 (2H, ddd, *J* = 10.0, 4.5 and 2.0 Hz, H-5), 3.43 (6H, s, OCH₃), 3.364 (6H, s, OCH₃), 3.361 (2H, *app.* t, *J* = 9.0 Hz, H-3), 3.27 (2H, dd, *J* = 10.0 and 9.0 Hz, H-4), 3.18 (2H, dd, *J* = 10.0 and 9.0 Hz, H-2); ¹³C NMR (125 MHz, CDCl₃) δ : 164.5 (C=N), 132.71 (ArC), 132.65 (ArCH), 129.0 (ArCH), 127.9 (ArCH), 86.0 & 85.9 (C-1 & C-3), 79.6 (C-5), 79.3 (C-4), 75.0 (C-2), 71.6 (C-6), 60.9 (OCH₃), 60.6 (OCH₃), 59.6 (OCH₃); *m/z* HRMS (ESI): Found [M+Na]⁺ 671.2424, C₃₂H₄₄N₂O₈S₂Na requires 671.2431; [α]_D²⁰ = -32 (*c* 0.4, CHCl₃).

1,3-Bis(phenyl 2-amino-3,4,6-tri-*O*-methyl-2,1-dideoxy-1-thio- β -D-glucopyranoside)imidazolium chloride (**9a**):


*Adapted from Huynh and co-workers.*³ To a solution of bis(imine) **S4** (490 mg, 0.75 mmol) in CH(OEt)₃ (2000 mol%) at rt, was added NH₄Cl (120 mol%) and the suspension was heated to 100 °C under an Ar atmosphere. After 14 h the reaction was allowed to cool to 60 °C and then placed under vacuum for 0.5 h to afford a residue. Purification by FCC (95:5 to 90:10 EtOAc:MeOH) yielded the imidazolium chloride **9a** (308 mg, 59%) as a hygroscopic beige solid. *R*_f = 0.4 (90:10 CH₂Cl₂:MeOH); ν_{max} / cm⁻¹ (film): 3318, 2927, 1735, 1474, 1444, 1258, 1105, 1051; ¹H NMR (400 MHz, CDCl₃) δ : 12.45 (1H, br s, CH Imidazolium), 7.43-7.40 (4H, m, ArCH), 7.32-7.27 (6H, m, ArCH), 6.93 (2H, s, CH Imidazolium), 5.97 (2H, d, *J* = 10.5 Hz, H-1), 4.33 (2H, dd, *J* = 10.5 and 9.0 Hz, H-3), 3.95 (2H, *app.* dt, *J* = 10.0 and 2.5 Hz, H-5), 3.82 (2H, *app.* t, *J* = 10.5 Hz, H-2), 3.70-3.62 (4H, m, H-6a &

H-6b), 3.51 (6H, s, OCH₃), 3.42 (6H, s, OCH₃), 3.37 (2H, dd, $J = 10.0$ and 9.0 Hz, H-4), 3.34 (6H, s, OCH₃); ¹³C NMR (100 MHz, CDCl₃) δ : 137.6 (CH Imidazolium), 133.0 (ArCH), 132.1 (ArC), 129.2 (ArCH), 128.5 (ArCH), 122.3 (CH Imidazolium), 85.2 (C-3), 83.0 (C-1), 79.7 (C-4), 78.6 (C-5), 70.4 (C-6), 65.0 (C-2), 61.5 (OCH₃), 59.9 (OCH₃), 59.3 (OCH₃); m/z HRMS (ESI): Found $[M-Cl]^+$ 661.2605, C₃₃H₄₅N₂O₅S₂ requires 661.2612; $[\alpha]^{21}_D = 20$ (c 0.9, CHCl₃).

[1,3-Bis(phenyl 2-amino-3,4,6-tri-*O*-methyl-2,1-dideoxy-1-thio- β -D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (12a):

Following General Procedure D. NHC-HCl **285a** (43.0 mg, 65.0 μ mol); in a modification of the general procedure, NaOt-Bu (6.2 mg, 65.0 μ mol) was used instead of KOt-Bu; FCC (100:0 to 98:2 CH₂Cl₂:MeOH) yielded **291a** (17.0 mg, 29%) as an orange oil; $R_f = 0.7$ (90:10 CH₂Cl₂:MeOH); $\nu_{max} / \text{cm}^{-1}$ (film): 2925, 1723, 1582, 1533, 1462, 1365, 1246, 1192, 1098; ¹H NMR (500 MHz, CDCl₃) *observed peaks* δ : 7.57-7.13 (12H, m, ArCH & CH Imidazolylidene), 6.04-3.98 (8H, m, H-Carbohydrate & CH COD), 3.68-2.87 (28H, m, H-Carbohydrate & CH COD), 2.55-1.65 (8H, m, CH₂ COD); ¹³C NMR (125 MHz, CDCl₃) *observed peaks* δ : 137.4, 132.9, 132.7, 132.0, 131.2, 129.8, 129.4, 129.2, 128.8, 128.5, 128.3, 128.2, 122.4, 97.8, 85.0, 83.0, 79.7, 78.5, 78.1, 77.4, 77.3, 77.0, 76.7, 70.5, 65.0, 61.5, 61.3, 59.9, 59.9, 59.4, 59.3, 59.2, 29.7; m/z HRMS (ESI): Found $[M]^+$ 871.2537, C₄₁H₅₆N₂O₁₀RhS₂ requires 871.2528; $[\alpha]^{22}_D = 102$ (c 0.1, CHCl₃).

Synthesis of a carbohydrate-based imidazolium salt with steric bulk at C3



General Hydrogenation Procedure: Pd/C Catalysed Azide Hydrogenation

To solution of azides **11**⁴ and **14a-e**⁴ (100 mol%) in EtOH (5% wt 12 M HCl, 0.2 M) under Ar at rt, was added Pd (5% wt on C, 10 mol%). H₂ (1 atm, balloon) was bubbled through the solvent until the Ar atmosphere was replaced. After 4 h, the H₂ was displaced by a stream of N₂ and the suspension was neutralised with sat. aq. NaHCO₃. The reaction mixture was filtered through Celite® using EtOH as eluent to afford a colourless solution. Concentration *in vacuo* and subsequent trituration with MeOH (3 x washes) yielded the amines **15a-e**.

Methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy-β-*D*-glucopyranoside (**8b**):

Following General Hydrogenation Procedure with some modifications. Azide **11**⁴ (1.15 g, 2.49 mmol); trituration with CHCl₃ (3 x 5 mL) yielded **8b** (932 mg, 86%) as colourless oil; *R*_f = 0.8 (90:10 CH₂Cl₂:MeOH); ν_{max} / cm⁻¹ (film): 3662, 2933, 1612, 1468, 1377, 1278, 1173, 1130, 1057, 1010; ¹H NMR (500 MHz, CDCl₃) δ: 7.57 (2H, br s, ArCH), 7.47 (1H, br s, ArCH), 4.24 (1H, dd, *J* = 9.5 and 8.5 Hz, H-3), 4.17 (1H, d, *J* = 8.0 Hz, H-1), 3.69 (1H, dd, *J* = 10.5 and 2.0 Hz, H-6a), 3.64 (1H, dd, *J* = 10.5 and 3.5 Hz, H-6b), 3.55 (3H, s, OCH₃), 3.49 (1H, dd, *J* = 9.5 and 8.5 Hz, H-4), 3.44 (1H, ddd, *J* = 9.5, 3.5 and 2.0 Hz, H-5), 3.43 (3H, s, OCH₃), 3.29 (3H, s, OCH₃), 3.05 (1H, dd, *J* = 9.5 and 8.0 Hz, H-2); ¹³C NMR (125 MHz, CDCl₃) δ: 160.4 (ArCOR), 133.0 (q, *J* = 33.5 Hz, ArCCF₃), 123.3 (q, *J* = 273.0 Hz, ArCCF₃), 116.8 (d, *J* = 4.0 Hz, ArCH), 115.2 (t, *J* = 4.0 Hz, ArCH), 104.5 (C-1), 85.7 (C-3), 79.3 (C-4), 74.9 (C-5), 71.0 (C-6), 60.4 (OCH₃), 59.5 (OCH₃), 57.4 (OCH₃), 57.0 (C-2); ¹⁹F NMR (470 MHz, CDCl₃) δ: -63.0 (CF₃); *m/z* HRMS (ESI): Found [M+H]⁺ 434.1392, C₁₇H₂₂NF₆O₅ requires 434.1397; [α]_D²³ = 45 (*c* 0.9, CHCl₃).

Methyl 2-amino-4,6-bis-O-methyl-3-O-(2',6'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside (15a):

Following General Hydrogenation Procedure with some modifications. Azide **14a**⁴ (600 mg, 1.31 mmol); trituration with CHCl₃ (3 x 5 mL) yielded **15a** (543 mg, 96%) as colourless solid; *R*_f = 0.8 (90:10 CH₂Cl₂:MeOH); *v*_{max} / cm⁻¹ (film): 3392, 2941, 1602, 1521, 1461, 1389, 1344, 1300, 1243, 1211, 1166, 1127, 1088, 1066; ¹H NMR (500 MHz, CDCl₃) δ: 7.78 (2H, d, *J* = 8.0 Hz, ArCH), 7.25 (br t, *J* = 8.0 Hz, ArCH), 4.72 (1H, *app.* t, *J* = 9.5 Hz, H-3), 4.68 (1H, d, *J* = 8.0 Hz, H-1), 3.65 (1H, br t, *J* = 9.0 Hz, H-4), 3.602 (1H, dd, *J* = 11.0 and 2.0 Hz, H-6a), 3.298 (3H, s, OCH₃), 3.51 (1H, dd, *J* = 11.0 and 4.0 Hz, H-6b), 3.36 (3H, s, OCH₃), 3.30 (1H, ddd, *J* = 9.5, 4.0 and 2.0 Hz, H-5), 3.22 (1H, dd, *J* = 10.0 and 8.0 Hz, H-2), 2.73 (3H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ: 154.3 (ArCOR), 131.4 (d, *J* = 5.0 Hz, ArCH), 124.6 (q, *J* = 31.0 Hz, ArCCF₃), 123.2 (q, *J* = 273.0 Hz, ArCCF₃), 123.1 (ArCH), 101.9 (C-1), 84.4 (C-3), 78.3 (C-4), 74.7 (C-5), 70.5 (C-6), 59.3 (OCH₃), 58.6 (OCH₃), 57.4 (OCH₃), 56.6 (C-2); ¹⁹F NMR (470 MHz, CDCl₃) δ: -62.9 (CF₃); *m/z* HRMS (ESI): Found [M+H]⁺ 434.1395, C₁₇H₂₂F₆NO₅ requires 434.1397; [α]²¹_D = -9 (*c* 0.8, CHCl₃).

Methyl 2-amino-4,6-bis-O-methyl-3-O-(2',4'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside (15b):

Following General Hydrogenation Procedure with some modifications. Azide **14b**⁴ (463 mg, 1.01 mmol); trituration with CHCl₃ (3 x 5 mL) yielded **15b** (425 mg, 97%) as colourless solid; *R*_f = 0.7 (90:10 CH₂Cl₂:MeOH); *v*_{max} / cm⁻¹ (film): 2939, 2841, 1628, 1594, 1508, 1348, 1315, 1287, 1262, 1124, 1083, 1055; ¹H NMR (500 MHz, CDCl₃) δ: 7.82 (1H, d, *J* = 2.0 Hz, ArCH), 7.72 (1H, dd, *J* = 9.0 and 2.5 Hz, ArCH), 7.51 (1H, d, *J* = 9.0 Hz, ArCH), 4.42 (1H, t, *J* = 9.5 Hz, H-3), 4.16 (1H, d, *J* = 8.0 Hz, H-1), 3.70 (1H, dd, *J* = 10.5 and 2.0 Hz, H-6a), 3.64 (1H, dd, *J* = 10.5 and 4.0 Hz, H-6b), 3.54 (3H, s, OCH₃), 3.53 (1H, dd, *J* = 10.0 and 9.0 Hz, H-4), 3.45 (1H, ddd, *J* = 10, 4.0 and 2.0 Hz, H-5), 3.43 (3H, s, OCH₃), 3.27 (3H, s, OCH₃), 3.11 (1H, dd, *J* = 9.5 and 8.0 Hz, H-2), 1.48 (2H, br s, NH₂); ¹³C NMR (125 MHz, CDCl₃) δ: 159.8 (ArCOR), 130.5 (q, *J* = 4.0 Hz, ArCH), 124.9-124.7 (m, ArCH), 123.6 (q, *J* = 271.5 Hz, ArCCF₃), 123.1 (q, *J* = 270.0 Hz, ArCCF₃), 123.0 (q, *J* = 34.0 Hz, ArCCF₃), 119.5 (q, *J* = 31.5 Hz, ArCCF₃), 115.2 (ArCH), 104.4 (C-1), 85.2 (C-3), 79.1 (C-4), 75.0 (C-5), 71.1 (C-6), 60.4 (OCH₃), 59.5 (OCH₃), 57.4 (OCH₃), 56.7 (C-2); ¹⁹F NMR (470 MHz, CDCl₃) δ: -62.0 (s, CF₃), -62.6 (s, CF₃); *m/z* HRMS (ESI): Found [M+H]⁺ 434.1383, C₁₇H₂₂F₆NO₅ requires 434.1397; [α]²³_D = 59 (*c* 0.6, CHCl₃).

Methyl 2-amino-4,6-bis-O-methyl-3-O-(2',3',5'-trifluoro)benzene-2-deoxy-β-D-glucopyranoside (15c):

According to General Hydrogenation Procedure. Azide **14c**⁴ (715 mg, 1.89 mmol); trituration yielded **15c** (581 mg, 87%) as a colourless solid which was contaminated by an unknown impurity (~10%); *R*_f = 0.7 (90:10 CH₂Cl₂:MeOH); ¹H NMR (400 MHz, CDCl₃) δ: 6.94 (1H, ddt, *J* = 10.5, 5.5 and 2.5 Hz, ArCH), 6.55 (1H, dddd, *J* = 10.0, 8.5, 5.5 and 2.5 Hz, ArCH), 4.15 (1H, d, *J* = 8.0 Hz, H-1), 4.09 (1H, *app.* t, *J* = ~9.0-9.5 Hz, H-3), 3.68 (1H, dd, *J* = 10.5 and 2.0 Hz, H-6a), 3.63 (1H, dd, *J* = 10.5 and 4.0 Hz, H-6b), 3.54 (3H, s, OCH₃), 3.50 (1H, dd, *J* = 9.5 and 9.0 Hz, H-4), 3.43 (3H, s, OCH₃), 3.41-3.38 (1H, m, H-5), 3.38 (3H, s, OCH₃), 3.09 (1H, dd, *J* = 9.5 and 8.0 Hz, H-2), 1.73 (2H, br s, NH₂); ¹³C NMR (125 MHz, CDCl₃) δ: 157.4 (ddd, *J* = 244.0, 13.5 and 4.0 Hz, ArCF), 151.0 (ddd, *J* = 248.5, 15.5 and 12.0 Hz, ArCF), 149.5 (dd, *J* = 8.5 and 4.5 Hz, ArC), 138.4 (ddd, *J* = 243.0, 13.5 and 5.0 Hz, ArCF), 104.2 (C-1), 101.1 (dd, *J* = 27.5 and 3.5 Hz, ArCH), 98.1 (dd, *J* = 28.0 and 21.5 Hz, ArCH), 87.6 (C-3), 78.9 (C-4), 74.9 (C-5), 70.9 (C-6), 60.4 (OCH₃), 59.4 (OCH₃), 57.2 (OCH₃), 56.7 (C-2);

^{19}F NMR (377 MHz, CDCl_3) δ : -114.3 – -114.4 (m, ArCF), -134.1 – -134.2 (m, ArCF), -163.6 – -163.7 (m, ArCF); m/z HRMS (ESI): Found $[\text{M}+\text{H}]^+$ 352.1363, $\text{C}_{15}\text{H}_{21}\text{F}_3\text{NO}_5$ requires 352.1366.


Methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy- β -D-glucopyranoside (15d):

Following General Hydrogenation Procedure with some modifications. Azide **14d**⁴ (963 mg, 2.04 mmol); trituration with CHCl_3 (3 x 5 mL) yielded **15d** (883 mg, 97%) as colourless oil; R_f = 0.7 (90:10 CH_2Cl_2 :MeOH); ν_{max} / cm^{-1} (film): 2931, 1725, 1511, 1495, 1488, 1441, 1196, 1083; ^1H NMR (500 MHz, CDCl_3) δ : 7.49-7.41 (5H, m, ArCH), 4.30 (1H, dd, J = 10.0 and 9.0 Hz, H-3), 4.15 (1H, d, J = 8.0 Hz, H-1), 3.68 (1H, dd, J = 11.0 and 2.0 Hz, H-6a), 3.66-3.59 (2H, m, H-4 & H-6b), 3.56 (OCH₃), 3.43 (OCH₃), 3.36 (OCH₃), 3.32 (1H, ddd, J = 9.5, 3.5 and 2.0 Hz, H-5), 3.11 (1H, *app.* t, J = 9.0 Hz, H-2); ^{13}C NMR (125 MHz, CDCl_3) δ : 144.3 (dddd, J = 246.0, 16.5, 8.0 and 4.0 Hz, ArCF), 141.1 (ddt, J = 246.0, 15.5 and 4.5 Hz, ArCF), 137.2 (ArC), 130.4 (t, J = 2.0 Hz, ArCH), 129.0 (ArCH), 128.7 (ArCH), 127.4 (ArC), 114.3 (t, J = 17.0 Hz, ArC), 104.9 (C-1), 88.2 (t, J = 2.5 Hz, C-3), 80.0 (C-4), 74.8 (C-5), 71.0 (C-6), 60.1 (OCH₃), 59.4 (OCH₃), 57.5 (OCH₃), 57.1 (C-2); ^{19}F NMR (470 MHz, CDCl_3) δ : -145.3 (dd, J = 22.5 and 8.5 Hz, ArCF), -156.0 (dd, J = 22.0 and 8.5 Hz, ArCF); m/z HRMS (ESI): Found $[\text{M}+\text{H}]^+$ 446.1585, $\text{C}_{21}\text{H}_{24}\text{F}_4\text{NO}_5$ requires 446.1585; $[\alpha]^{22}_{\text{D}}$ = -32 (*c* 0.3, CHCl_3).

Methyl 2-amino-4,6-di-*O*-methyl-3-*O*-1'-(4'-cyano)naphthlene-2-deoxy- β -D-glucopyranoside (15e):

Following General Hydrogenation Procedure with some modifications. Azide **14e**⁴ (963 mg, 2.04 mmol); trituration with CHCl_3 (3 x 5 mL) yielded **15e** (896 mg, 90%) as colourless oil; R_f = 0.7 (90:10 CH_2Cl_2 :MeOH); ν_{max} / cm^{-1} (film): 2930, 2218, 1577, 1509, 1391, 1324, 1228, 1057; ^1H NMR (400 MHz, CDCl_3) δ : 8.37 (1H, ddd, J = 8.5, 1.5 and 0.5 Hz, ArCH), 8.20 (1H, dt, J = 8.5 and 1.5 Hz, ArCH), 7.85 (1H, d, J = 8.0 Hz, ArCH), 7.71 (1H, ddd, J = 8.5, 7.0 and 1.5 Hz, ArCH), 7.61 (1H, ddd, J = 8.0, 7.0 and 1.5 Hz, ArCH), 7.31 (1H, d, J = 8.5 Hz, ArCH), 4.56 (1H, br t, J = 9.5 Hz, H-3), 4.22 (1H, d, J = 8.0 Hz, H-1), 3.72 (1H, dd, J = 11.0 and 2.0 Hz, H-6a), 3.67 (1H, dd, J = 11.0 and 3.5 Hz, H-6b), 3.63 (1H, br t, J = 9.5 Hz, H-4), 3.57 (3H, s, OCH₃), 3.49 (1H, ddd, J = 9.5, 3.5 and 2.0 Hz, H-5), 3.45 (3H, s, OCH₃), 3.24 (3H, s, OCH₃), 3.22 (1H, dd, J = 9.5 and 8.0 Hz, H-2); ^{13}C NMR (100 MHz, CDCl_3) δ : 159.2 (ArCOR), 134.1 (ArCH), 134.0 (ArC), 129.1 (ArCH), 127.1 (ArCH), 125.6 (ArC), 125.3 (ArCH), 122.6 (ArCH), 118.4 (ArCCN), 107.1 (ArCH), 104.6 (C-1), 102.6 (ArCCN), 85.3 (C-3), 79.2 (C-4), 75.0 (C-5), 71.1 (C-6), 60.6 (OCH₃), 59.5 (OCH₃), 57.5 (OCH₃), 57.2 (C-2); m/z HRMS (ESI): Found $[\text{M}+\text{H}]^+$ 373.1760, $\text{C}_{20}\text{H}_{25}\text{N}_2\text{O}_5$ requires 373.1758; $[\alpha]^{22}_{\text{D}}$ = 8 (*c* 0.2, CHCl_3).

Synthesis of complexes 12b and 17a-e



General Procedure A. Bis(imine) Synthesis 1.

Adapted from Kündig and co-workers.⁵ To a solution of **amine** (100 mol%) in CH₂Cl₂ (0.4 M) at rt, was added Na₂SO₄ (1 g per mmol of amine), formic acid (7 mol%) and glyoxal (40% by wt in H₂O, 50 mol%). After stirring for 16 h the solution was filtered and then concentrated. Purification by trituration with **solvent** (3 x washes) yielded the **bis(imine)** as a colourless solid. Note: the bis(imine)s were generally insoluble in MeOH and soluble in CHCl₃.

General Procedure B. Bis(imine) Synthesis 2

To a solution of **amine** (100 mol%) and glyoxal (aq. 40%, 50 mol%) in anhydrous MeOH (0.5 M) at rt, was added MgSO₄ (0.5 g per mmol). After 18 h, the reaction was diluted with CHCl₃ (10 mL), filtered and then concentrated. Purification by trituration with cool **solvent** (3 x 5 mL) yielded **bis(imine)** as a colourless solid. Note: bis(imine)s were generally insoluble in MeOH and soluble in CHCl₃.

General Procedure C. Imidazolium Chloride Synthesis with MOMCl

To a solution of **bis(imine)** (100 mol%) in anhydrous THF (0.2 M) at rt, was added MOMCl (2000 mol%). After 16 h, the reaction was concentrated and the resulting residue was further purified by FCC to yield the **imidazolium chloride**.

General Procedure D. NHC.HCl Ligation to [Rh(COD)Cl]⁺

Adapted from Ekkehardt and co-workers.⁶ To a solution of **imidazol(in)ium chloride** (100 mol%) and KO^t-Bu (100 mol%) in N₂ sat. anhydrous THF (0.01 M) at rt, was added [Rh(COD)Cl]₂ (50 mol%). After 14 h, the reaction was concentrated *in vacuo*, suspended in CH₂Cl₂ and filtered through Celite®. The filtrate was concentrated to afford a residue. Purification by FCC yielded the [RhNHC(COD)Cl] complex.

Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)-*N,N'*-iminoethylidene (S5):

Following General Procedure A. Amine **8b** (913 mg, 2.11 mmol); trituration with MeOH yielded **S5** (742 mg, 79%) as a colourless solid; *R*_f = 0.9 (90:10 CH₂Cl₂:MeOH); ν_{max} / cm⁻¹ (film): 3661, 2987, 2901, 1623, 1611, 1468, 1405, 1393, 1369, 1276, 1169, 1126, 1065, 1056, 1038; ¹H NMR (500 MHz, CDCl₃) δ : 7.83 (2H, s, HC=N), 7.29 (4H, d, *J* = 1.5 Hz, ArCH), 7.25 (2H, t, *J* = 1.5 Hz, ArCH), 4.49 (2H, d, *J* = 7.5 Hz, H-1), 4.47 (2H, *app.* t, *J* = 9.5

Hz, H-3), 3.70 (2H, dd, $J = 10.5$ and 2.0 Hz, H-6a), 3.65 (2H, dd, $J = 10.5$ and 3.5 Hz, H-6b), 3.56 (2H, dd, $J = 10.0$ and 9.0 Hz, H-4), 3.48 (6H, s, OCH₃), 3.48 (2H, ddd, $J = 10.0$, 3.5 and 2.0 Hz, H-5), 3.44 (6H, s, OCH₃), 3.36 (2H, m, found $J = 7.5$ Hz, H-2), 3.35 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 165.3 (HC=N), 160.2 (ArCOR), 132.4 (q, $J = 33.5$ Hz, ArCCF₃), 123.1 (q, $J = 272.5$ Hz, ArCCF₃), 117.5 (br s, ArCH), 115.1 (br s, ArCH), 102.0 (C-1), 84.7 (C-3), 78.9 (C-4), 75.4 (C-2), 74.8 (C-5), 70.9 (C-6), 60.5 (OCH₃), 59.5 (OCH₃), 57.3 (OCH₃); ¹⁹F NMR (377 MHz, CDCl₃) δ : -63.1 (CF₃); m/z HRMS (ESI): Found [M+H]⁺ 889.2562, C₃₆H₄₁N₂F₁₂O₁₀ requires 889.2564; [α]_D²⁰ = -59 (c 0.7, CHCl₃).

Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',6'-trifluoromethyl)benzene-2-deoxy- β -D-glucopyranoside)-*N,N'*-iminoethylidene (S6a):

Following General Procedure A with some modifications. Amine **15a** (660 mg, 1.52 mmol); after filtration to remove the desiccant, concentration afforded the crude product, contaminated with the starting material. Dissolution of the residue in a small quantity of Et₂O and then the addition of hexane precipitated unreacted starting material. Decanting the solvent and its subsequent concentration yielded **S6a** (257 mg, 39%) as a colourless solid; $R_f = 0.9$ (90:10 CH₂Cl₂:MeOH); $\nu_{\max} / \text{cm}^{-1}$ (film): 2935, 2888, 2842, 1635, 1602, 1460, 1380, 1343, 1300, 1286, 1246, 1210, 1165, 1130, 1088, 1065; ¹H NMR (500 MHz, CDCl₃) δ : 7.60 (2H, s, HC=N), 7.55 (4H, d, $J = 8.0$ Hz, ArCH), 6.89 (2H, t, $J = 8.0$ Hz, ArCH), 4.73 (2H, *app.* t, $J = 9.0$ Hz, H-3), 4.49 (2H, d, $J = 7.5$ Hz, H-1), 3.65 (2H, *app.* t, $J = 9.5$ Hz, H-4), 3.64 (2H, dd, $J = 11.0$ and 2.0 Hz, H-6a), 3.56 (2H, dd, $J = 11.0$ and 4.0 Hz, H-6b), 3.44 (6H, s, OCH₃), 3.42-3.40 (2H, m, H-2), 3.39 (6H, s, OCH₃), 3.34 (2H, ddd, $J = 9.5$, 4.0 and 2.0 Hz, H-5), 2.94 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 165.4 (HC=N), 154.8 (ArCOR), 131.0 (ArCH), 124.2 (br q, $J = 31.0$ Hz, ArCCF₃), 123.7 (q, $J = 274.0$ Hz, ArCCF₃), 122.3 (ArCH), 102.2 (C-1), 84.6 (C-3), 78.2 (C-4), 74.8 (C-5), 74.6 (C-2), 70.9 (C-6), 59.4 (OCH₃), 59.1 (OCH₃), 57.2 (OCH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ : -59.4 (CF₃); m/z HRMS (ESI): Found [M+H]⁺ 889.2577, C₃₆H₄₁F₁₂N₂O₁₀ requires 889.2564; [α]_D²² = 25 (c 0.6, CHCl₃).

Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',4'-trifluoromethyl)benzene-2-deoxy- β -D-glucopyranoside)-*N,N'*-iminoethylidene (S6b):

Following General Procedure A. Amine **15b** (172 mg, 0.40 mmol); trituration with MeOH yielded **S6b** (89.4 mg, 52%) as a colourless solid; $R_f = 0.9$ (90:10 CH₂Cl₂:MeOH); $\nu_{\max} / \text{cm}^{-1}$ (film): 2929, 2888, 1631, 1594, 1514, 1450, 1386, 1352, 1319, 1292, 1264, 1218, 1178, 1135, 1085, 1055, 1024; ¹H NMR (500 MHz, CDCl₃) δ : 7.70 (2H, s, HC=N), 7.66 (2H, dd, $J = 9.0$ and 2.5 Hz, ArCH), 7.52 (2H, d, $J = 2.5$ Hz, ArCH), 7.38 (2H, d, $J = 9.0$ Hz, ArCH), 4.82 (2H, *app.* ddd, $J = 10.0$, 9.0 and 6.0 Hz, H-3), 4.54 (2H, d, $J = 7.5$ Hz, H-1), 3.70 (2H, dd, $J = 10.5$ and 1.5 Hz, H-6a), 3.64 (2H, dd, $J = 10.5$ and 2.5 Hz, H-6b), 3.55-3.52 (4H, m, H-4 & H-5), 3.48 (6H, s, OCH₃), 3.43 (6H, s, OCH₃), 3.33 (2H, dd, $J = 9.5$ and 7.5 Hz, H-2), 3.15 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 165.6 (HC=N), 158.8 (ArCOR), 130.3 (ArCH), 124.3 (br s, ArCH), 123.8 (q, $J = 273.0$ Hz, ArCCF₃), 122.56 (q, $J = 32.5$ Hz, ArCCF₃), 122.54 (q, $J = 272.0$ Hz, ArCCF₃), 118.7 (q, $J = 31.5$ Hz, ArCCF₃), 114.4 (ArCH), 102.2 (C-1), 80.6 (C-2), 79.3 (C-4 or C-5), 75.3 (C-2), 74.8 (C-4 or C-5), 70.9 (C-6), 60.4 (OCH₃), 59.5 (OCH₃), 57.3 (OCH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ : -62.1 (s, CF₃), -63.5 (s, CF₃); m/z HRMS (ESI): Found [M+Na]⁺ 911.2381, C₃₆H₄₀F₁₂N₂O₁₀Na requires 911.2384; [α]_D²⁰ = 8 (c 0.8, CHCl₃).

Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',3',5'-trifluoro)benzene-2-deoxy- β -D-glucopyranoside)-*N,N'*-iminoethylidene (S6c):

Following General Procedure B. Amine **15c** (546 mg, 1.55 mmol); trituration solvent: MeOH (2 x 5 mL) yielded **S6c** (546 mg, 97%) as a colourless solid which was contaminated by an unknown impurity (~10%); R_f = 0.9 (90:10 CH₂Cl₂:MeOH); ¹H NMR (500 MHz, CDCl₃) δ : 7.82 (2H, s, HC=N), 6.68 (2H, ddt, J = 10.5, 5.5 and 2.5 Hz, ArCH), 6.40 (2H, dddd, J = 10.0, 8.5, 5.5 and 3.0 Hz, ArCH), 4.50 (2H, d, J = 7.5 Hz, H-1), 4.37 (2H, *app.* t, J = 9.5 Hz, H-3), 3.70 (2H, dd, J = 10.5 and 2.0 Hz, H-6a), 3.64 (2H, dd, J = 10.5 and 4.0 Hz, H-6b), 3.57 (1H, dd, J = 9.5 and 9.0 Hz, H-4), 3.47 (6H, s, OCH₃), 3.47-3.44 (2H, m, H-5), 3.44 (6H, s, OCH₃), 3.40 (6H, s, OCH₃), 3.37 (2H, dd, J = 9.5 and 7.5 Hz, H-2); ¹³C NMR (125 MHz, CDCl₃) δ : 165.2 (C=N), 157.1 (ddd, J = 244.0, 14.0 and 3.5 Hz, ArCF), 150.7 (ddd, J = 248.5, 15.5 and 12.0 Hz, ArCF), 149.2-149.0 (m, ArC), 138.5 (ddd, J = 244.0, 14.0 and 5.0 Hz, ArCF), 102.0 (C-1), 101.0 (dd, J = 27.5 and 3.0 Hz, ArCH), 97.9 (dd, J = 27.5 and 22.0 Hz, ArCH), 85.3 (C-3), 78.6 (C-4), 75.3 (C-2), 74.8 (C-5), 70.8 (C-6), 60.5 (OCH₃), 59.4 (OCH₃), 57.1 (OCH₃); ¹⁹F NMR (470 MHz, CDCl₃) *major compound* δ : -115.0 (q, J = 10.0 Hz, ArCF), -134.7 (dd, J = 19.0 and 10.0 Hz, ArCF), -164.0 (td, J = 11.5 and 5.5 Hz, ArCF). *Impurity* δ : -120.1 (t, J = 11.0 Hz, ArCF), 139.0 (d, J = 20.0 Hz, ArCF). *m/z* HRMS (ESI): Found [M+H]⁺ 725.2507, C₃₂H₃₉N₂O₁₀ requires 725.2503.

Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy- β -D-glucopyranoside)-*N,N'*-iminoethylidene (S6d):

Following General Procedure A. Amine **15d** (905 mg, 2.03 mmol); trituration with MeOH yielded **S6d** (577 mg, 62%) as a colourless solid; R_f = 0.9 (90:10 CH₂Cl₂:MeOH); ν_{\max} / cm⁻¹ (film): 2937, 2879, 2843, 1632, 1512, 1488, 1438, 1382, 1197, 1138, 1116, 1080, 1054, 1020; ¹H NMR (500 MHz, CDCl₃) δ : 7.92 (2H, s, HC=N), 7.37-7.35 (6H, m, ArCH), 7.26-7.23 (4H, m, ArCH), 4.58 (2H, *app.* t, J = 9.0 Hz, H-3), 4.52 (2H, d, J = 8.0 Hz, H-1), 3.71 (2H, dd, J = 11.0 and 2.0 Hz, H-6a), 3.70 (2H, *app.* t, J = 9.0 Hz, H-4), 3.64 (2H, dd, J = 11.0 and 3.5 Hz, H-6b), 3.48 (6H, s, OCH₃), 3.45 (2H, dd, J = 9.5 and 8.0 Hz, H-2), 3.44 (6H, s, OCH₃), 3.42 (2H, ddd, J = 9.5, 3.5 and 2.0 Hz, H-5), 3.38 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 165.5 (HC=N), 144.1 (dddd, J = 246.0, 12.0, 8.0 and 4.0 Hz, ArCF), 141.0 (ddt, J = 247.5, 16.0 and 3.5 Hz, ArCF), 136.8 (t, J = 12.0 Hz, ArC), 130.2 (ArCH), 128.8 (ArCH), 128.5 (ArCH), 127.3 (ArC), 114.4 (t, J = 17.0 Hz, ArC), 102.2 (C-1), 85.8 (C-3), 79.5 (C-4), 75.1 (C-2), 74.7 (C-5), 71.0 (C-6), 60.3 (OCH₃), 59.5 (OCH₃), 57.4 (OCH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ : -146.1 (dd, J = 22.0 and 8.5 Hz, ArCF), -156.0 (dd, J = 22.0 and 8.5 Hz, ArCF); *m/z* HRMS (ESI): Found [M+Na]⁺ 935.2755, C₄₄H₄₄F₈N₂O₁₀Na requires 935.2760; [α]_D²¹ = -104 (*c* 0.6, CHCl₃).

Bis(methyl 2-amino-4,6-di-*O*-methyl-3-*O*-1'-(4'-cyano)naphthlene-2-deoxy- β -D-glucopyranoside)-*N,N'*-iminoethylidene (S6e):

Following General Procedure A. Amine **15e** (651 mg, 1.75 mmol); trituration with MeOH yielded **S6e** (449 mg, 67%) as a colourless solid; R_f = 0.9 (90:10 CH₂Cl₂:MeOH); ν_{\max} / cm⁻¹ (film): 2934, 2838, 2217, 1632, 1577, 1509, 1462, 1428, 1388, 1322, 1277, 1244, 1277, 1135, 1119, 1112, 1105, 1016, 1014; ¹H NMR (400 MHz, CDCl₃) δ : 7.93-7.90 (4H, m, ArCH), 7.73 (2H, s, N=CH), 7.54 (2H, d, J = 8.5 Hz, ArCH), 7.38 (2H, ddd, J = 8.5, 7.0 and 1.0 Hz, ArCH), 7.17 (2H, ddd, J = 8.5, 7.0 and 1.0 Hz, ArCH), 6.98 (2H, d, J = 8.5 Hz, ArCH), 4.78 (2H, t, J = 9.0 Hz, H-3), 4.50 (2H, d, J = 7.5 Hz, H-1), 3.69 (2H, dd, J = 10.5 and 2.0 Hz, H-6a), 3.62 (2H, dd, J = 10.5 and 3.5 Hz, H-6b), 3.60 (2H, t, J = 9.5 Hz, H-4), 3.49 (2H, ddd, J = 9.5, 3.5 and 2.0 Hz, H-5), 3.47 (6H, s, OCH₃),

3.42 (6H, s, OCH₃), 3.41 (2H, dd, *J* = 9.5 and 7.5 Hz, H-2), 3.10 (6H, s, OCH₃); ¹³C NMR (100 MHz, CDCl₃) δ: 165.0 (C=N), 158.7 (ArCOR), 133.5 (ArCH), 133.4 (ArC), 128.9 (ArCH), 126.6 (ArCH), 125.04 (ArC), 124.95 (ArCH), 122.1 (ArCH), 118.3 (ArCCN), 107.2 (ArCH), 102.3 (ArCCN), 102.0 (C-1), 83.0 (C-3), 79.1 (C-4), 75.4 (C-2), 74.9 (C-5), 70.9 (C-6), 60.5 (OCH₃), 59.5 (OCH₃), 57.3 (OCH₃); *m/z* HRMS (ESI): Found [M+H]⁺ 767.3286, C₄₂H₄₇N₄O₁₀ requires 767.3287; [α]²¹_D = 10 (*c* 0.8, CHCl₃).

1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)imidazolium chloride (9b):

Following General Procedure C. Bis(imine) **S5** (340 mg, 0.39 mmol); FCC (100:0 to 96:4 CH₂Cl₂:MeOH) yielded **9b** (201 mg, 56%) as a tan amorphous solid; *R_f* = 0.6 (90:10 CH₂Cl₂:MeOH); *v*_{max} / cm⁻¹ (film): 3276, 2929, 1659, 1560, 1591, 1469, 1372, 1283, 1230, 1178, 1136, 1120, 1102, 1058, 1008; ¹H NMR (500 MHz, CD₃OD) δ: 7.97 (2H, br s, CH_{imidazolium}), 7.55 (2H, br s, ArCH), 7.54 (4H, br s, ArCH), 5.31 (2H, dd, *J* = 10.5 and 8.5 Hz, H-3), 4.83 (2H, d, *J* = 8.5 Hz, H-1), 4.57 (2H, dd, *J* = 10.5 and 8.5 Hz, H-2), 3.77-3.70 (6H, m, H-5 & H-6a & H-6b), 3.67 (2H, dd, *J* = 9.5 and 8.5 Hz, H-4), 3.44 (6H, s, OCH₃), 3.29 (6H, s, OCH₃), 3.20 (6H, s, OCH₃), *CH*_{imidazolium} undergoes exchange in CD₃OD and was not observed; ¹³C NMR (125 MHz, CDCl₃) δ: 160.4 (ArCOR), 139.6 (t, *J* = 33.0 Hz, CD_{imidazolium}), 134.0 (q, *J* = 33.5 Hz, ArCCF₃), 124.4 (q, *J* = 272.0 Hz, ArCCF₃), 122.3 (CH_{imidazolium}), 117.5 (ArCH), 116.6 (ArCH), 100.7 (C-1), 81.0 (C-3 & C-4), 75.9 (C-5), 71.5 (C-6), 65.5 (C-2), 60.9 (OCH₃), 59.6 (OCH₃), 57.2 (OCH₃); ¹⁹F NMR (283 MHz, CDCl₃) δ: -60.4 (CF₃); *m/z* HRMS (ESI): Found [M-Cl]⁺ 901.2566, C₃₇H₄₁N₂O₁₀ requires 901.2564; [α]²¹_D = 45 (*c* 0.6, CH₃OH).

1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',6'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)imidazolium chloride (16a):

Following General Procedure C. Bis(imine) **15a** (70 mg, 0.08 mmol); FCC (100:0 to 95:5 CH₂Cl₂:MeOH) yielded **16a** (59.2 mg) as a tan amorphous solid; *R_f* = 0.5 (90:10 CH₂Cl₂:MeOH); *v*_{max} / cm⁻¹ (film): 2982, 1603, 1462, 1344, 1300, 1243, 1212, 1134, 1090; ¹H NMR (500 MHz, CDCl₃) δ: 12.19 (1H, s, CH_{imidazolium}), 7.76 (4H, d, *J* = 8.0 Hz, ArCH), 7.26 (2H, t, *J* = 8.0 Hz, ArCH), 7.05 (2H, s, CH_{imidazolium}), 6.16 (2H, d, *J* = 8.0 Hz, H-1), 5.12 (2H, *app.* t, *J* = 9.5 Hz, H-3), 4.19 (2H, *app.* t, *J* = ~9.0 Hz, H-2), 3.89-3.80 (4H, m, H-4 & H-5), 3.69 (6H, s, OCH₃), 3.65 (2H, dd, *J* = 11.0 and 2.0 Hz, H-6a), 3.51 (2H, dd, *J* = 11.0 and 4.0 Hz, H-6b), 3.35 (6H, s, OCH₃), 2.66 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ: 153.3 (ArCOR), 136.7 (CH_{imidazolium}), 131.3 (ArCH), 124.1 (br, ArCCF₃), 123.4 (ArCH), 123.1 (q, *J* = 272.5 Hz, ArCCF₃), 122.9 (CH_{imidazolium}), 99.1 (C-1), 84.6 (C-3), 78.0 & 73.6 (C-4 & C-5), 70.0 (C-6), 66.9 (C-2), 59.2 (OCH₃), 58.1 (OCH₃), 57.3 (OCH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ: -59.2 (CF₃); *m/z* HRMS (ESI): Found [M-Cl]⁺ 901.2571, C₃₇H₄₁F₁₂N₂O₁₀ requires 901.2564; [α]²²_D = 58 (*c* 0.7, CHCl₃).

1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',4'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)imidazolium chloride (16b):

Following General Procedure C. Bis(imine) **15b** (90 mg, 0.10 mmol); FCC (100:0 to 96:4 CH₂Cl₂:MeOH) yielded **16b** (80.0 mg) as a tan amorphous solid; *R_f* = 0.5 (90:10 CH₂Cl₂:MeOH); *v*_{max} / cm⁻¹ (film): 2939, 1627, 1597, 1509, 1384, 1347, 1286, 1260, 1220, 1180, 1122, 1100, 1084, 1053, 1003; ¹H NMR (500 MHz, CDCl₃) δ: 12.31 (1H, s, CH_{imidazolium}), 7.95 (2H, d, *J* = 9.0 Hz, ArCH), 7.80 (2H, dd, *J* = 9.0 and 2.5 Hz, ArCH), 7.67 (2H, d, *J* =

2.5 Hz, ArCH), 7.05 (2H, s, CH Imidazolium), 6.04 (2H, dd, $J = 10.5$ and 8.5 Hz, H-3), 4.86 (2H, d, $J = 8.0$ Hz, H-1), 4.05 (2H, dd, $J = 10.5$ and 8.0 Hz, H-2), 3.92 (2H, dt, $J = 10.0$ and 2.5 Hz, H-5), 3.67-3.63 (6H, m, H-4 & H-6a & H-6b), 3.39 (6H, s, OCH₃), 3.21 (6H, s, OCH₃), 2.77 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 158.0 (ArCOR), 135.6 (CH Imidazolium), 131.4 (d, $J = 4.0$ Hz, ArCH), 124.4-124.1 (m, ArCH), 123.50 (q, $J = 33.5$ Hz, ArCCF₃), 123.46 (q, $J = 271.5$ Hz, ArCCF₃), 123.0 (CH Imidazolium), 121.8 (q, $J = 273.0$ Hz, ArCCF₃), 118.8 (q, $J = 31.5$ Hz, ArCCF₃), 115.4 (ArCH), 100.8 (C-1), 79.4 (C-4), 79.3 (C-3), 74.2 (C-5), 69.9 (C-6), 66.1 (C-2), 60.4 (OCH₃), 59.4 (OCH₃), 56.9 (OCH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ : -62.2 (CF₃), -62.9 (CF₃); m/z HRMS (ESI): Found [M-Cl]⁺ 901.2563, C₃₇H₄₁F₁₂N₂O₁₀ requires 901.2564. [α]²²_D = 75 (*c* 2.5, CHCl₃).

1,3-Bis(methyl 2-amino-4-6-bis-*O*-methyl-3-*O*-(2',3',5'-trifluoro)benzene-2-deoxy- β -D-glucopyranoside)imidazolium chloride (16c):

Following General Procedure C. Bis(imine) **S5c** (520 mg, 0.72 mmol); FCC (99:1 to 90:10 CH₂Cl₂:MeOH) yielded **16c** (345 mg, 62%) as a hygroscopic beige solid which was contaminated by an unknown impurity (~10%); $R_f = 0.6$ (90:10 CH₂Cl₂:MeOH); ¹H NMR (400 MHz, CDCl₃) δ : 12.16 (1H, s, CH Imidazolium), 7.24 (2H, CH Imidazolium), 7.06 (2H, m, ArCH), 6.49 (2H, dddd, $J = 11.0, 8.5, 5.5$ and 3.0 Hz, ArCH), 5.49 (2H, d, $J = 8.0$ Hz, H-1), 5.31 (2H, *app.* t, $J = 9.5$ Hz, H-3), 4.09 (2H, dd, $J = 10.5$ and 8.0 Hz, H-2), 3.92 (2H, *app.* dt, $J = 10.0$ and 2.5 Hz, H-5), 3.71-3.66 (6H, m, H-4 & H-6a & H-6b), 3.42 (6H, s, OCH₃), 3.33 (6H, s, OCH₃), 3.24 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 157.6 (ddd, $J = 245.5, 14.0$ and 3.65 Hz, ArCF), 150.8 (ddd, $J = 249.0, 15.5$ and 12.5 Hz, ArCF), 148.1-147.8 (m, ArC), 134.4 (ddd, $J = 243.0, 14.5$ and 5.5 Hz, ArCF), 136.4 (CH Imidazolium), 123.0 (CH Imidazolium), 101.1 (dd, $J = 27.5$ and 3.5 , ArCH), 99.9 (C-1), 98.8 (dd, $J = 27.5$ and 21.5 Hz, ArCH), 83.0 (C-3), 79.4 (C-4), 74.1 (C-5), 70.0 (C-6), 66.4 (C-2), 60.3 (OCH₃), 59.4 (OCH₃), 57.2 (OCH₃); ¹⁹F NMR (377 MHz, CDCl₃) δ : -112.7 (q, $J = 9.5$ Hz, ArCF), -133.6 (dd, $J = 20.5$ and 10.0 Hz, ArCF), 163.7 (ddt, $J = 22.0, 11.5$ and 6.0 Hz, ArCF); m/z HRMS (ESI): Found [M]⁺ 737.2522, C₃₃H₃₉F₆N₂O₁₀ requires 737.2503.

1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy- β -D-glucopyranoside)imidazolium chloride (16d):

Following General Procedure C. Bis(imine) **15d** (310 mg, 0.34 mmol); FCC (98:2 to 95:5 CH₂Cl₂:MeOH) yielded **16d** (169 mg, 52%) as a tan amorphous solid; $R_f = 0.4$ (90:10 CH₂Cl₂:MeOH); ν_{\max} / cm⁻¹ (film): 2935, 2850, 1512, 1488, 1441, 1196, 1136, 1084, 1071; ¹H NMR (500 MHz, CDCl₃) δ : 12.51 (1H, s, CH Imidazolium), 7.48-7.36 (10H, m, ArCH), 7.21 (2H, d, $J = 1.5$ Hz, CH Imidazolium), 6.02 (2H, d, $J = 8.5$ Hz, H-1), 5.06 (2H, dd, $J = 10.5$ and 8.5 Hz, H-3), 4.25 (2H, dd, $J = 10.5$ and 8.5 Hz, H-2), 3.95 (2H, *app.* dt, $J = 10.0$ and 2.0 Hz, H-5), 3.89 (2H, br t, $J = 9.0$ Hz, H-4), 3.74 (2H, dd, $J = 11.0$ and 2.0 Hz, H-6a), 3.66 (6H, s, OCH₃), 3.62 (2H, dd, $J = 11.0$ and 2.5 Hz, H-6b), 3.44 (6H, s, OCH₃), 3.36 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 144.2 (ddd, $J = 247.5, 6.5$ and 2.5 Hz, ArCF), 141.1 (ddt, $J = 246.5, 15.5$ and 4.5 Hz, ArCF), 137.6 (CH Imidazolium), 136.0 (tt, $J = 12.0$ and 3.0 Hz, ArC), 130.2 (ArCH), 129.2 (ArCH), 128.7 (ArCH), 127.0 (ArC), 123.0 (CH Imidazolium), 115.5 (t, $J = 17.0$ Hz, ArC), 99.7 (C-1), 85.8 (C-3), 80.0 (C-4), 73.6 (C-5), 70.2 (C-6), 66.8 (C-2), 59.7 (OCH₃), 59.3 (OCH₃), 57.5 (OCH₃); ¹⁹F NMR (470 MHz, CDCl₃) δ : -144.4 (dd, $J = 22.5$ and 8.5 Hz, ArCF), -157.0 (dd, $J = 23.0$ and 8.5 Hz, ArCF); m/z HRMS (ESI): Found [M-Cl]⁺ 925.2944, C₄₅H₄₅N₂F₈O₁₀ requires 925.2941; [α]²¹_D = 32 (*c* 0.6, CHCl₃).

1,3-Bis(methyl 2-amino-4,6-di-*O*-methyl-3-*O*-1'-(4'-cyano)naphthlene-2-deoxy- β -D-glucopyranoside)imidazolium chloride (16e):

Following General Procedure C. Bis(imine) **15e** (200 mg, 0.26 mmol); FCC (95:5 PhMe:MeOH) yielded **16e** (164 mg, 77%) as a tan amorphous solid; R_f = 0.3 (90:10 CH₂Cl₂:MeOH); ν_{\max} / cm⁻¹ (film): 2939, 2219, 1577, 1509, 1463, 1388, 1324, 1246, 1084; ¹H NMR (500 MHz, CDCl₃) δ : 12.35 (1H, s, CH Imidazolium), 8.12 (2H, dt, J = 8.5 and 1.0 Hz, ArCH), 8.10 (2H, dt, J = 8.5 and 1.0 Hz, ArCH), 7.86 (2H, d, J = 8.5 Hz, ArCH), 7.67-7.63 (4H, m, ArCH), 7.53 (2H, ddd, J = 8.5, 7.0 and 1.0 Hz, ArCH), 6.93 (2H, d, J = 1.5 Hz, CH Imidazolium), 6.08 (2H, dd, J = 10.5 and 8.5 Hz, H-3), 5.12 (2H, d, J = 8.0 Hz, H-1), 4.11 (2H, dd, J = 10.5 and 8.0 Hz, H-2), 3.99 (2H, dt, J = 10.0 and 2.5 Hz, H-5), 3.74 (2H, dd, J = 10.0 and 8.5 Hz, H-4), 3.69-3.67 (4H, m, H-6a & H-6b), 3.40 (6H, s, OCH₃), 3.14 (6H, s, OCH₃), 2.78 (6H, s, OCH₃); ¹³C NMR (125 MHz, CDCl₃) δ : 157.0 (ArCOR), 136.1 (CH Imidazolium), 134.3 (ArCH), 133.5 (ArC), 129.0 (ArCH), 127.0 (ArCH), 125.2 (ArCH), 124.7 (ArC), 122.8 (CH Imidazolium), 121.8 (ArCH), 117.8 (ArCCN), 107.0 (ArCH), 102.9 (ArCCN), 100.2 (C-1), 79.5 (C-3), 79.4 (C-4), 74.1 (C-5), 69.8 (C-6), 66.4 (C-2), 60.3 (OCH₃), 59.3 (OCH₃), 56.7 (OCH₃); m/z HRMS (ESI): Found [M-Cl]⁺ 779.3292, C₄₃H₄₇N₄O₁₀ requires 779.3287; [α]_D²¹ = 91 (c 0.7, CHCl₃).

[1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy- β -D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (12b):

Following General Procedure D with some modifications. NHC.HCl **9b** (40 mg, 43 μ mol); sealed tube and heated at 100 °C for 16 h; FCC (100:0 to 99:1 CH₂Cl₂:MeOH) yielded **12b** (35.1 mg, 72%) as an orange oil; R_f = 0.8 (90:10 CH₂Cl₂:MeOH); ν_{\max} / cm⁻¹ (film): 2934, 1610, 1468, 1386, 1276, 1171, 1132, 1032, 1010; ¹H NMR (500 MHz, CDCl₃) δ : 7.88 (2H, s, ArCH), 7.41 (1H, s, ArCH), 7.38 (1H, s, ArCH), 7.22 (2H, s, ArCH), 6.95 (1H, d, J = 2.0 Hz, CH Imidazolylidene), 6.80 (1H, s, CH Imidazolylidene), 6.35 (1H, br s, H-Carbohydrate), 5.50 (1H, br s, H-Carbohydrate), 5.17-5.11 (1H, m, CH COD), 4.94 (1H, br s, CH COD), 4.66 (1H, br s, H-Carbohydrate), 4.55 (1H, *app.* d, J = 9.0 Hz, H-Carbohydrate), 4.47 (1H, d, J = 8.0 Hz, H-Carbohydrate), 4.06-3.99 (1H, m, H-Carbohydrate), 3.99-3.94 (1H, m, CH COD), 3.85-3.72 (3H, m, H-Carbohydrate & H-Carbohydrate & H-6a & H-6b), 3.70-3.61 (H-Carbohydrate & H-6a & H-6b), 3.49 (3H, s, OCH₃), 3.46 (3H, s, OCH₃), 3.45 (3H, s, OCH₃), 3.41 (3H, s, OCH₃), 3.35 (3H, s, OCH₃), 3.28 (3H, s, OCH₃), 3.17 (1H, br s, CH COD), 2.43-2.32 (4H, m, CHH COD), 1.97-1.76 (4H, m, CHH COD). *Only observed 13 carbohydrate protons.* ¹³C NMR (125 MHz, CDCl₃) δ : 189.2 (*app.* br s, C Carbene), 160.1 (ArC), 159.5 (ArC), 132.9 (q, J = 33.5 Hz, ArCCF₃), 132.4 (q, J = 33.5 Hz, ArCCF₃), 123.2 (q, J = 272.5 Hz, ArCCF₃), 123.1 (q, J = 272.5 Hz, ArCCF₃), 118.8 (br s, CH Imidazolylidene), 117.7 (CH Imidazolylidene & ArCH), 116.3 (br, ArCH), 115.5 (m, ArCH), 103.2 (C-Carbohydrate), 101.8 (C-Carbohydrate), 99.2 (d, J = 5.5 Hz, CH COD), 98.3 (d, J = 7.0 Hz, CH COD), 83.0 (C-Carbohydrate & C-Carbohydrate), 78.8 (C-Carbohydrate), 78.2 (C-Carbohydrate), 75.9 (C-Carbohydrate), 75.8 (C-Carbohydrate), 73.5 (C-6), 71.3 (C-6), 69.9-69.5 (m, CH COD & CH COD), 67.4, 64.3 (C-Carbohydrate), 60.6 (OCH₃), 60.2 (OCH₃), 59.6 (OCH₃), 59.4 (OCH₃), 57.1 (OCH₃), 56.8 (OCH₃), 33.1 (CH₂ COD), 32.5 (CH₂ COD), 29.1 (CH₂ COD) 28.9 (CH₂ COD); ¹⁹F NMR (283 MHz, CDCl₃) δ : -62.6 (CF₃), -63.0 (CF₃); m/z HRMS (ESI): Found [M-Cl]⁺ 1111.2472, C₄₅H₅₂F₁₂N₂O₁₀Rh requires 1111.2480; [α]_D²¹ = -47 (c 1.2, CHCl₃).

[1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',6'-trifluoromethyl)benzene-2-deoxy- β -D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (17a):

Following General Procedure D with some modifications. NHC.HCl **16a** (45 mg, 0.046 mmol); sealed tube and heated at 100 °C for 16 h; FCC (100:0 to 98:2 CH₂Cl₂:MeOH) yielded **291c** (21.8 mg, 40%) as an orange oil; *R_f* = 0.5 (90:10 CH₂Cl₂:MeOH); ν_{max} / cm⁻¹ (film): 2937, 2835, 1602, 1459, 1343, 1300, 1242, 1210, 1165, 1128, 1088; ¹H NMR (500 MHz, CDCl₃) *observed peaks* δ : 7.84 (4H, m, ArCH), 7.23-7.17 (2H, m, ArCH), 7.11 (1H, d, *J* = 2.0 Hz, CH Imidazolylidene), 7.05 (1H, d, *J* = 2.0 Hz, CH Imidazolylidene), 6.44 (1H, d, *J* = 5.0 Hz, H-Carbohydrate), 5.19 (1H, br s, H-Carbohydrate), 5.04 (1H, s, H-Carbohydrate), 4.95 (1H, q, *J* = 7.5 Hz, CH COD), 4.89-4.84 (3H, m, H-Carbohydrate & H-Carbohydrate & CH COD), 4.39 (1H, t, *J* = 9.5 Hz, H-Carbohydrate), 3.89 (1H, t, *J* = 9.5 Hz, H-Carbohydrate), 3.85 (1H, m, CH COD), 3.78-3.74 (1H, m, CH COD), 3.74-3.69 (2H, m, H-Carbohydrate & H-6a), 3.68-3.63 (2H, m, H-Carbohydrate & H-6b), 3.59-3.53 (H-6a & H-6b), 3.52 (3H, s, OCH₃), 3.49 (3H, s, OCH₃), 3.44 (3H, s, OCH₃), 3.39 (3H, s, OCH₃), 2.86 (6H, s, OCH₃), 2.59-2.51 (1H, m, CHH COD), 2.46 (1H, ddt, *J* = 15.0, 10.0 and 7.5 Hz, CHH COD), 2.37-2.21 (2H, m, CHH COD & CHH COD), 2.01 (1H, dd, *J* = 16.0 and 7.0 Hz, CHH COD), 1.91-1.84 (1H, m, CHH COD), 1.81-1.70 (2H, m, CHH COD & CHH COD); ¹³C NMR (125 MHz, CDCl₃) *observed peaks* δ : 185.8 (d, *J* = 47.5 Hz, C Carbene), 155.4 (ArC), 154.1 (ArC), 132.0 (ArCH), 131.4 (ArCH), 130.9 (ArCH), 122.9 (ArCH), 122.6 (ArCH), 121.5 (CH Imidazolylidene), 118.5 (CH Imidazolylidene), 102.8 (C-1), 102.6 (C-1), 98.5 (d, *J* = 6.5 Hz, CH COD), 97.0 (d, *J* = 5.0 Hz, CH COD), 86.1 (C-Carbohydrate), 85.1 (C-Carbohydrate), 78.6 (C-Carbohydrate), 77.9 (C-Carbohydrate), 76.6 (C-Carbohydrate), 75.8 (C-Carbohydrate), 74.7 (C-6), 71.4 (C-6), 70.6 (d, *J* = 14.0 Hz, CH COD), 67.5 (C-Carbohydrate), 66.8 (d, *J* = 13.0 Hz, CH COD), 65.0 (C-Carbohydrate), 59.4 (OCH₃), 59.3 (OCH₃), 58.6 (OCH₃), 58.3 (OCH₃), 57.6 (OCH₃), 56.6 (OCH₃), 33.7 (CH₂ COD), 31.8 (CH₂ COD), 29.9 (CH₂ COD), 27.9 (CH₂ COD); ¹⁹F NMR (470 MHz, CDCl₃) δ : -58.8 (CF₃), -59.0 (CF₃); *m/z* HRMS (ESI): Found [M-Cl]⁺ 1111.2495, C₄₅H₅₂N₂O₁₀Rh requires 1111.2480; [α]_D²³ = 31 (*c* 0.6, CHCl₃).

[1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',4'-trifluoromethyl)benzene-2-deoxy- β -D-glucopyranoside)(chloro)(1,5-cyclooctadiene)rhodium(I) (17b):

Following General Procedure D with some modifications. NHC.HCl **16b** (50 mg, 53 μ mol); sealed tube and heated at 100 °C for 16 h; FCC (100:0 to 95:5 CH₂Cl₂:MeOH) yielded **17b** (60.8 mg, 99%) as an orange oil; *R_f* = 0.7 (90:10 CH₂Cl₂:MeOH); ν_{max} / cm⁻¹ (film): 2937, 1627, 1595, 1509, 1347, 1315, 1284, 1262, 1220, 1178, 1125, 1084, 1054; ¹H NMR (500 MHz, CDCl₃) δ : 7.93 (1H, br s, ArCH), 7.85 (1H, d, *J* = 2.5 Hz, ArCH), 7.77 (1H, dd, *J* = 9.0 and 2.5 Hz, ArCH), 7.69 (1H, d, *J* = 2.5 Hz, ArCH), 7.57 (1H, dd, *J* = 9.0 and 2.5 Hz, ArCH), 7.22 (1H, d, *J* = 2.0 Hz, CH Imidazolylidene), 7.16 (1H, d, *J* = 9.0 Hz, ArCH), 6.78 (1H, d, *J* = 2.0 Hz, CH Imidazolylidene), 6.33 (1H, br s, H-carbohydrate), 6.17 (1H, br s, H-carbohydrate), 4.99 (1H, tt, *J* = 9.0 and 2.5 Hz, CH COD), 4.95 (1H, br s, H-carbohydrate), 4.79 (1H, br s, H-carbohydrate), 4.66 (1H, q, *J* = 7.5 Hz, CH COD), 4.28 (1H, br s, H-carbohydrate), 4.07 (1H, *app.* dt, *J* = 7.0 and 1.5 Hz, H-carbohydrate), 3.93 (1H, ddd, 10.0, 4.0 and 2.0 Hz, H-5), 3.78 (1H, dd, *J* = 11.0 and 2.0 Hz, H-6a), 3.73 (1H, dd, *J* = 10.0 and 6.5 Hz, H-6a), 3.72 (1H, dd, *J* = 11.0 and 4.0 Hz, H-6b), 3.66-3.61 (1H, m, H-carbohydrate), 3.61 (3H, s, OCH₃), 3.56 (1H, dd, *J* = 10.0 and 7.0 Hz, H-6b), 3.50 (3H, s, OCH₃), 3.48 (3H, s, OCH₃), 4.43 (1H, br s, H-carbohydrate), 3.36 (2H, br s, CH COD), 3.28 (3H, s, OCH₃), 3.15 (3H, s, OCH₃), 2.71 (3H, s, OCH₃), 2.61 (1H, br s, CH₂ COD), 2.55-2.46 (1H, m, CH₂ COD), 2.24-2.11 (2H, m, CH₂ COD), 2.06-1.93 (2H, m, CH₂ COD), 1.77-1.69 (1H, m, CH₂ COD), 1.63-1.57 (1H, m, CH₂ COD). *Only observed 13 carbohydrate protons.* ¹³C NMR (125 MHz, CDCl₃) *observed peaks* δ : 183.7 (br d, *J* = 50.0 Hz, C Imidazolylidene), 158.5 (ArCOR), 157.0 (ArCOR), 130.8 (d, *J* = 4.0 Hz, ArCH), 130.0 (d, *J* = 4.0 Hz, ArCH), 125.1 (br s, ArCH), 123.9 (br s, ArCH), 123.8 (q, *J* = 271.0 Hz, ArCCF₃), 123.7 (q, *J* = 271.0 Hz, ArCCF₃), 123.0 (q, *J* = 32.0 Hz, ArCCF₃), 122.3 (q, *J* = 33.0 Hz, ArCCF₃),

119.5 (br s, CH Imidazolylidene), 119.5 (br s, CH Imidazolylidene), 119.2 (q, $J = 32.0$ Hz, ArCCF₃), 118.0 (q, $J = 32.0$ Hz, ArCCF₃), 116.5 (br s, ArCH), 113.8 (s, ArCH), 100.3 (C carbohydrate), 98.8 (d, $J = 7.0$ Hz, CH COD), 98.0 (d, $J = 7.0$ Hz, CH COD), 81.7 (C carbohydrate), 80.0 (C carbohydrate), 75.7 (C carbohydrate), 74.5 (C carbohydrate), 74.2 (C carbohydrate), 73.4 (C carbohydrate), 72.4 (C carbohydrate), 71.0 (C carbohydrate), 67.9 (d, $J = 16.0$ Hz, CH COD), 67.6 (C carbohydrate), 62.5 (C carbohydrate), 56.0 (OCH₃), 59.52 (OCH₃), 59.47 (C carbohydrate), 59.0 (OCH₃), 56.8 (OCH₃), 56.5 (OCH₃), 54.8 (OCH₃), 33.7 (CH₂ COD), 31.5 (CH₂ COD), 31.0 (CH₂ COD), 27.1 (CH₂ COD); ¹⁹F NMR (470 MHz, CDCl₃) δ : -61.89 (CF₃), -61.92 (CF₃), -62.1 (CF₃), -62.3 (CF₃); m/z HRMS (ESI): Found [M-Cl]⁺ 1111.2456, C₄₅H₅₂F₁₂N₂O₁₀Rh requires 1111.2480; [α]_D²¹ = 81 (c 1.9, CHCl₃).

[1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',3',5'-trifluoro)benzene-2-deoxy- β -D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (17c):

Following General Procedure D. NHC.HCl **16c** (20.0 mg, 26.0 μ mol), FCC (100:0 to 98:2 CH₂Cl₂:MeOH) yielded **17c** (15.5 mg, 69%) as an orange oil which was contaminated by an unknown impurity (~10%); $R_f = 0.7$ (90:10 CH₂Cl₂:MeOH); ν_{\max} / cm⁻¹ (film): 2924, 1632, 1515, 1453, 1124, 1087; ¹H NMR (500 MHz, CDCl₃) *observed peaks* δ : 7.10 (1H, d, $J = 2.0$ Hz, CH Imidazolylidene), 6.92 (1H, d, $J = 2.0$ Hz, CH Imidazolylidene), 6.85-6.68 (2H, m, ArCH), 6.52-6.41 (2H, m, ArCH), 5.05-4.97 (2H, m), 4.90-4.84 (2H, m), 4.83-4.68 (1H, br s), 3.97-3.92 (1H, m), 3.89-3.85 (1H, br s), 3.81-3.62 (8H, m), 3.59-3.53 (3H, m), 3.51-3.45 (8H, m), 3.43-3.36 (7H, m), 3.30-3.20 (3H, br s), 2.59-2.46 (1H, br s), 2.46 (3H, m), 2.03-1.80 (4H, m); ¹³C NMR (125 MHz, CDCl₃) *observed peaks* δ : 171.12, 137.85, 129.02, 128.20, 125.28, 122.90 (br, CH Imidazolylidene), 99.75, 79.33, 79.25, 77.27, 77.01, 76.76, 76.08, 73.89, 72.07, 70.11, 69.89, 66.73, 66.28, 64.17, 60.38, 60.28, 60.14, 59.35, 59.34, 59.26, 59.18, 57.07, 57.00, 32.54, 31.92, 29.69, 29.65, 29.35, 22.68, 21.44, 21.03, 14.19, 14.10; ¹⁹F NMR (377 MHz, CDCl₃) δ : -114.3 (q, $J = 11.0$ Hz, ArCF), -119.5 (q, $J = 11.0$ Hz, ArCF), -138.4 (br s, ArCF), -163.7 (br, s, ArCF); m/z HRMS (ESI): Found [M]⁺ 947.2419, C₄₁H₅₀F₆N₂O₁₀Rh requires 947.2410; [α]_D²² = 5 (c 0.2, CHCl₃).

[1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy- β -D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (17d):


Following General Procedure D with some modifications. NHC.HCl **16d** (52 mg, 54 μ mol); sealed tube and heated at 100 °C for 16 h; FCC (100:0 to 98:2 CH₂Cl₂:MeOH) yielded **17d** (40.6 mg, 64%) as an orange oil; $R_f = 0.5$ (90:10 CH₂Cl₂:MeOH); ν_{\max} / cm⁻¹ (film): 2932, 2834, 1650, 1486, 1440, 1196, 1079; ¹H NMR (500 MHz, CDCl₃) δ : 7.41-7.28 (10H, m, ArCH), 7.11-7.08 (2H, m, CH Imidazolylidene), 6.48 (1H, br s, H-Carbohydrate), 5.09-5.04 (2H, m, H-Carbohydrate & CH COD), 4.95-4.82 (3H, m, H-Carbohydrate & H-Carbohydrate & CH COD), 4.18 (1H, *app.* t, $J = 9.5$ Hz, H-Carbohydrate), 3.88 (1H, *app.* t, $J = 7.0$ Hz, H-Carbohydrate), 3.85-3.73 (5H, m, H-Carbohydrate & H-Carbohydrate & CH COD & H-6a & H-6b), 3.69-3.61 (3H, m CH COD & H-6a & H-6b), 3.56 (OCH₃), 3.50 (OCH₃), 3.48 (OCH₃), 3.46 (OCH₃), 3.43 (OCH₃), 3.36 (OCH₃), 2.64-2.32 (4H, m, CHH COD), 2.05-1.79 (4H, m, CHH COD). *Only observed 13 carbohydrate protons*; ¹³C NMR (125 MHz, CDCl₃) δ : 185.8 (*app.* br s, C Carbene), 144.1 (br d, $J = 245.0$ Hz, ArCF & ArCF), 141.2 (dd, $J = 246.0$ and 15.0 Hz, ArCF), 140.8 (dd, $J = 247.0$ and 16.0 Hz, ArCF), 136.5 (br s, ArC), 135.8 (br s, ArC), 130.2 (ArCH), 130.1 (ArCH), 128.8 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 127.3 (ArC), 127.1 (ArC), 117.5 (CH Imidazolylidene & CH Imidazolylidene), 114.5 (t, $J = 17.0$ Hz, ArC), 114.1 (t, $J = 17.0$ Hz, ArC), 103.5 (C-Carbohydrate), 101.9 (C-Carbohydrate), 98.8 (d, $J = 6.5$ Hz, CH COD), 97.1 (br s, CH COD), 84.5 (C-Carbohydrate), 79.4 (C-Carbohydrate), 79.3 (C-Carbohydrate), 77.3 (C-Carbohydrate), 76.5 (C-Carbohydrate), 75.1 (C-Carbohydrate), 73.8

(C-6), 71.4 (C-6), 70.5 (br s, CH COD), 67.9 (br s, CH COD), 64.87, 60.5 (OCH₃), 59.3 (OCH₃), 59.2 (OCH₃), 57.4 (OCH₃) 56.9 (OCH₃), 33.3 (CH₂ COD), 32.0 (CH₂ COD), 29.7 (CH₂ COD), 28.2 (CH₂ COD); ¹⁹F NMR (470 MHz, CDCl₃) δ: -145.5 (CF), -145.8 (CF), -156.3 (CF), -157.3 (CF); *m/z* HRMS (ESI): Found [M-Cl]⁺ 1135.2867, C₅₃H₅₆F₈N₂O₁₀Rh requires 1135.2857; [α]²¹_D = -1 (c 0.7, CHCl₃).

[1,3-Bis(methyl 2-amino-4,6-di-*O*-methyl-3-*O*-1'-(4'-cyano)naphthlene-2-deoxy-β-D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (17e):


Following General Procedure D with some modifications. NHC.HCl **16e** (28.0 mg, 54.0 μmol); sealed tube and heated at 100 °C for 16 h; FCC (100:0 to 98:2 CH₂Cl₂:MeOH) yielded **17e** (29.3 mg, 82%) as an orange oil; *R_f* = 0.9 (90:10 CH₂Cl₂:MeOH); *v*_{max} / cm⁻¹ (film): 3074, 2929, 2834, 2217, 1575, 1462, 1427, 1387, 1323, 1278, 1244, 1228, 1100, 1082, 1061, 1015; ¹H NMR (500 MHz, CDCl₃) δ: 8.55 (1H, d, *J* = 8.5 Hz, ArCH), 8.30 (1H, d, *J* = 8.5 Hz, ArCH), 8.16 (1H, d, *J* = 8.5 Hz, ArCH), 8.13 (1H, d, *J* = 8.5 Hz, ArCH), 7.84 (1H, d, *J* = 8.0 Hz, ArCH), 7.69-7.56 (5H, m, ArCH), 8.17 (1H, br s, CH Imidazolylidene), 7.05 (1H, br s, CH Imidazolylidene) 6.92 (2H, br s, ArCH), 6.21 (1H, br s, H-Carbohydrate), 5.77 (1H, br s, H-Carbohydrate), 5.11 (1H, br s, H-Carbohydrate), 4.96 (1H, d, *J* = 6.0 Hz, H-Carbohydrate), 4.81 (1H, td, *J* = 8.0 and 4.0 Hz, CH COD), 4.37 (1H, d, *J* = 8.0 Hz, CH COD), 4.00 (1H, td, *J* = 6.0 and 3.0 Hz, H-Carbohydrate), 3.93 (1H, ddd, 9.5, 4.5 and 2.5 Hz, H-Carbohydrate), 3.86 (1H, br s, H-Carbohydrate), 3.77-3.61 (4H, m, H-Carbohydrate), 3.56 (3H, s, OCH₃), 3.54-3.49 (1H, m, H-Carbohydrate), 3.47 (3H, s, OCH₃), 3.45 (3H, s, OCH₃), 3.45-3.28 (4H, m, H-Carbohydrate & H-Carbohydrate & CH COD & CH COD), 3.16 (3H, s, OCH₃), 3.15 (3H, s, OCH₃), 2.79 (3H, s, OCH₃), 2.47-2.29 (2H, m, CHH COD), 2.16-2.09 (1H, m, CHH COD), 1.93-1.80 (3H, m, CHH COD), 1.66-1.56 (2H, m, CHH COD); ¹³C NMR (125 MHz, CDCl₃) *observed peaks* δ: 185.7 (br s, C Carbene), 157.5, 156.7, 134.0, 133.9, 133.8, 133.6, 129.0, 128.9, 126.9, 126.8, 125.5, 125.2, 125.2, 125.1, 123.4, 122.7, 119.6, 118.5, 118.3, 107.48, 106.2, 102.6, 102.1, 100.7, 98.7, 97.7, 81.3, 79.1, 76.8, 76.2, 75.7, 75.5, 75.3, 74.7, 73.5, 73.0, 72.5, 71.9, 70.7, 68.6, 68.1, 67.4, 63.9, 60.2, 59.5, 59.1, 57.6, 57.2, 55.7, 33.2, 32.3, 29.7, 28.1; *m/z* HRMS (ESI): Found [M-Cl]⁺ 989.3193, C₅₁H₅₈N₄O₁₀Rh requires 989.3202; [α]²¹_D = 111 (c 0.9, CHCl₃).

Asymmetric Catalysis:




General Procedure F. Asymmetric Rh-Catalysed Hydrosilylation: To a solution of **complex** (2 mol%) in anhydrous hexane (1 mL, 0.5 M) at rt, was added Ph₂SiH₂ (0.28 mL, 300 mol%) and **ketone** (0.5 mmol, 100 mol%) and the solution was stirred for 18 h. Desilylation was mediated by the addition of MeOH (3.0 mL) and K₂CO₃ (30.0 mg). The solution was stirred for 2 h and then concentrated *in vacuo*. Purification of the title compound was accomplished by FCC which yielded the product **alcohol**.

Following General Procedure E. Complex **12a** (9.1 mg); ketone **2** (58.3 μL); FCC (hexane:Et₂O 85:15) yielded **3** (45.8 mg, 75%) as a colourless oil; the enantiomeric excess of **3** was determined by chiral HPLC (Chiralpak IB, hexane:I-PrOH 97:3, 0.5 mL min⁻¹, 20.0 °C); *t_R* (major) = 18.5 min and *t_R* (minor) = 20.1 min.



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	20.326	BB	0.3456	3469.70337	151.28224	29.9830
2	23.374	BB	0.4780	8102.51660	268.55630	70.0170

Following General Procedure E. Complex **17c** (9.8 mg); ketone **2** (58.3 μ L); FCC (hexane:Et₂O 85:15) yielded **3** (54.4 mg, 89%) as a colourless oil; the enantiomeric excess of **3** was determined by chiral HPLC (Chiralpak IB, hexane:*i*-PrOH 97:3, 0.5 mL min⁻¹, 20.0 °C); *t*_R (major) = 18.5 min and *t*_R (minor) = 20.1 min.



Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	19.867	BB	0.3197	2100.09668	99.72891	86.4289
2	22.841	BBA	0.3418	329.75827	14.92120	13.5711



References:

1. Still, W. C.; Kahn, M.; Mitra, A., Rapid chromatographic technique for preparative separations with moderate resolution. *J. Org. Chem.* **1978**, *43* (14), 2923-2925.
2. Buskas, T.; Garegg, P. J.; Konradsson, P.; Maloisel, J. L., Facile Preparation of Glycosyl Donors for Oligosaccharide Synthesis - 2-Azido-2-Deoxyhexopyranosyl Building-Blocks. *Tetrahedron-Asymmetr* **1994**, *5* (11), 2187-2194.
3. Huynh, H. V.; Han, Y.; Jothibasu, R.; Yang, J. A., C-13 NMR Spectroscopic Determination of Ligand Donor Strengths Using N-Heterocyclic Carbene Complexes of Palladium(II). *Organometallics* **2009**, *28* (18), 5395-5404.
4. Henderson, A. S.; Medina, S.; Bower, J. F.; Galan, M. C., Nucleophilic Aromatic Substitution (S_NAr) as an Approach to Challenging Carbohydrate-Aryl Ethers. *Organic Letters* **2015**, *17* (19), 4846-4849.

5. Jia, Y. X.; Katayev, D.; Bernardinelli, G.; Seidel, T. M.; Kundig, E. P., New chiral N-heterocyclic carbene ligands in palladium-catalyzed alpha-arylations of amides: conformational locking through allylic strain as a device for stereocontrol. *Chemistry* **2010**, *16* (21), 6300-9.
6. Paas, M.; Wibbeling, B.; Frohlich, R.; Hahn, F. E., Silver and rhodium complexes of stable, monomeric imidazolidin-2-ylidenes: Synthesis, reactivity and decomposition pathway. *Eur J Inorg Chem* **2006**, (1), 158-162.


NMR data

¹H NMR (500 MHz, CDCl₃) Bis(phenyl 2-amino-3,4,6-tri-*O*-methyl-2,1-dideoxy-1-thio-β-D-glucopyranoside)-*N,N'*-iminoethylidene (S4):





^{13}C NMR (125 MHz, CDCl_3)


ah87724_ah07575bf_CARBON_01





¹H NMR (500 MHz, CDCl₃) 1,3-Bis(phenyl 2-amino-3,4,6-tri-*O*-methyl-2,1-dideoxy-1-thio-β-D-glucopyranoside)imidazolium chloride (9a).




HSQC (CDCl₃)





^1H NMR (500 MHz, CDCl_3) [1,3-Bis(phenyl 2-amino-3,4,6-tri-*O*-methyl-2,1-dideoxy-1-thio- β -D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (12a):



^{13}C NMR (125 MHz, CDCl_3)




¹H NMR (500 MHz, CDCl₃) Methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside (8b):




¹³C NMR (125 MHz, CDCl₃)



ah9409_ah10819a_CARBON01




^{19}F NMR (470 MHz, CDCl_3)




¹H NMR (500 MHz, CDCl₃) Methyl 2-amino-4,6-bis-O-methyl-3-O-(2',6'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside (15a):





^{13}C NMR (125 MHz, CDCl_3)



^{19}F NMR (470 MHz, CDCl_3)




¹H NMR (500 MHz, CDCl₃) Methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',4'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside (15b):




¹³C NMR (125 MHz, CDCl₃)



ah18504_ah09717a_CARBON_001



¹⁹F NMR (470 MHz, CDCl₃)




¹H NMR (500 MHz, CDCl₃) Methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',3',5'-trifluoro)benzene-2-deoxy-β-*D*-glucopyranoside (15c):




¹³C NMR (125 MHz, CDCl₃)

ah17977_ah08672pcA_CARBON_001





^{19}F NMR (377 MHz, CDCl_3)

cg/ah13689_669
single_pulse




¹H NMR (500 MHz, CDCl₃) Methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy-β-D-glucopyranoside (15d):




¹³C NMR (125 MHz, CDCl₃)



ah18833_ah09773_CARBON_001




^{19}F NMR (470 MHz, CDCl_3)





¹H NMR (500 MHz, CDCl₃) Methyl 2-amino-4,6-di-O-methyl-3-O-1'-(4'-cyano)naphthlene-2-deoxy-β-D-glucopyranoside (15e):




^{13}C NMR (125 MHz, CDCl_3)




¹H NMR (500 MHz, CDCl₃) Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)-*N,N'*-iminoethylidene (S5):





¹³C NMR (125 MHz, CDCl₃)



^{19}F NMR (377 MHz, CDCl_3)




¹H NMR (500 MHz, CDCl₃) Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',6'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)-*N,N'*-iminoethylidene (S6a):




¹³C NMR (125 MHz, CDCl₃)



ah18797_ah09763_CARBON_001




¹⁹F NMR (470 MHz, CDCl₃)





¹H NMR (500 MHz, CDCl₃) Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',4'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)-*N,N'*-iminoethylidene (S6b):




¹³C NMR (125 MHz, CDCl₃)



¹H NMR (500 MHz, CDCl₃) Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',3',5'-trifluoro)benzene-2-deoxy-β-*D*-glucopyranoside)-*N,N'*- iminoethylidene (S6c):




¹³C NMR (125 MHz, CDCl₃)





¹⁹F NMR (470 MHz, CDCl₃)

ah18048_as7584_FLUORINE_001




¹H NMR (500 MHz, CDCl₃) Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy-β-D-glucopyranoside)-*N,N'*-iminoethylidene (S6d):




¹³C NMR (125 MHz, CDCl₃)

ah18892_ah09783trit_CARBON_001





¹⁹F NMR (470 MHz, CDCl₃)


ah18892_ah09783trit_FLUORINE_001





¹H NMR (500 MHz, CDCl₃) Bis(methyl 2-amino-4,6-di-*O*-methyl-3-*O*-1'-(4'-cyano)naphthlene-2-deoxy-β-*D*-glucopyranoside)-*N,N'*-iminoethylidene (S6e):



¹³C NMR (125 MHz, CDCl₃)




¹H NMR (500 MHz, CDCl₃) 1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)imidazolium chloride (9b):




¹³C NMR (125 MHz, CDCl₃)

ah9459_ah10828a_CARBON01





^{19}F NMR (283 MHz, CDCl_3)


cg/ah10632_828
single_pulse



¹H NMR (500 MHz, CDCl₃) 1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',6'-trifluoromethyl)benzene-2-deoxy-β-*D*-glucopyranoside)imidazolium chloride (16a):




¹³C NMR (125 MHz, CDCl₃)





¹⁹F NMR (470 MHz, CDCl₃)

cg/ah23092_765A
single_pulse




¹H NMR (500 MHz, CDCl₃) 1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',4'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)imidazolium chloride (16b):




¹³C NMR (125 MHz, CDCl₃)

ah18634_ah09739pcA_CARBON_001





¹⁹F NMR (470 MHz, CDCl₃)

ah18634_ah09739pcA_FLUORINE_001




¹H NMR (500 MHz, CDCl₃) 1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',3',5'-trifluoro)benzene-2-deoxy-β-D-glucopyranoside)imidazolium chloride (16c):




¹³C NMR (125 MHz, CDCl₃)

ah18071_ah08686B_CARBON_001





¹⁹F NMR (377 MHz, CDCl₃)


cg/ah19217_686B
single_pulse



¹H NMR (500 MHz, CDCl₃) 1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy-β-D-glucopyranoside)imidazolium chloride (16d):




¹³C NMR (125 MHz, CDCl₃)





¹⁹F NMR (470 MHz, CDCl₃)


ah18955_ah09794pcA_FLUORINE_001





¹H NMR (500 MHz, CDCl₃) 1,3-Bis(methyl 2-amino-4,6-di-*O*-methyl-3-*O*-1'-(4'-cyano)naphthlene-2-deoxy-β-*D*-glucopyranoside)imidazolium chloride (16e):



¹³C NMR (125 MHz, CDCl₃)




¹H NMR (500 MHz, CDCl₃) [1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(3',5'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (12b):




¹³C NMR (125 MHz, CDCl₃)

832/11
carbon





¹⁹F NMR (283 MHz, CDCl₃)


cg/ah10714_8232a
single_pulse



¹H NMR (500 MHz, CDCl₃) [1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',6'-trifluoromethyl)benzene-2-deoxy-β-D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (17a):




¹³C NMR (125 MHz, CDCl₃)





¹⁹F NMR (470 MHz, CDCl₃)

cg/ah24364_801b
single_pulse




^1H NMR (500 MHz, CDCl_3) [1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',4'-trifluoromethyl)benzene-2-deoxy- β -D-glucopyranoside)](chloro)(1,5-cyclooctadiene)rhodium(I) (17b):




¹³C NMR (125 MHz, CDCl₃)

ah18786_ah09760pcA_CARBON_001





¹⁹F NMR (470 MHz, CDCl₃)

ah18786_ah09760pcA_FLUORINE_001




¹H NMR (500 MHz, CDCl₃) [1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(2',3',5'-trifluoro)benzene-2-deoxy-β-D-glucopyranoside)imidazol-2-ylidene] (chloro)(1,5-cyclooctadiene)rhodium(I) (17c):




¹³C NMR (125 MHz, CDCl₃)

ah18080_ah08686B_CARBON_001




¹⁹F NMR (377 MHz, CDCl₃)

cg/ah19310_688A
single_pulse




¹H NMR (500 MHz, CDCl₃) [1,3-Bis(methyl 2-amino-4,6-bis-*O*-methyl-3-*O*-(4'-phenyl-2',3',5',6'-tetrafluoro)benzene-2-deoxy-β-D-glucopyranoside)imidazol-2-ylidene](chloro)(1,5-cyclooctadiene)rhodium(I) (17d):




¹³C NMR (125 MHz, CDCl₃)



Cryo/11
C 2000scan



¹⁹F NMR (470 MHz, CDCl₃)



¹H NMR (500 MHz, CDCl₃) [1,3-Bis(methyl 2-amino-4,6-di-*O*-methyl-3-*O*-1'-(4'-cyano)naphthlene-2-deoxy-β-D-glucopyranoside)imidazol-2-ylidene](chloro) (1,5-cyclooctadiene)rhodium(I) (17e):



¹³C NMR (125 MHz, CDCl₃)

cryoprobe/11

